Business Standard

Elder Pharma launches anti-fungal drug in India

Launched Zalain to treat fungal skin infections, plans to launch upto five nutraceutical products in India through partnerships with intt firms in 6 months

Press Trust of India  |  New Delhi 

  • ALSO READ

    Visually-challenged students observe World Environment Day

    Lupin receives USFDA approval for antibiotic capsules

    Sensex pares early gains but holds on to 16,000 level

    Sensex pares early gains but holds on to 16,000 level

    Re gains 27 paise Vs dollar to hit 1-week high in early trade

Elder Pharmaceuticals today said it has launched 'Zalain', a medicine used to treat fungal skin infections, in India in association with Spain-based drug firm Ferrer.

"Zalain has been introduced in India as part of company's strategy to strengthen its anti-infectives division which stood at about Rs 113.61 crore in FY 2012 and contributed 10% to the total revenue," Elder Pharmaceuticals Ltd Joint Managing Director Alok Saxena said in a statement.

The company is also planning to launch up to five in India through partnerships with international firms in next six months as it looks to strengthen position in the segment in the domestic market.

The Mumbai-based drug firm at present markets various nutraceutical products in the country, including calcium supplement 'Shelcal'. Its product portfolio consists licensed as well as own brands.

Elder Pharma's revenues for the financial year ended March 2012 stood at Rs 981.89 crore.

Shares of today closed at Rs 302.15 on the BSE, up 2.25% from its previous close.

Elder Pharma launches anti-fungal drug in India

Launched Zalain to treat fungal skin infections, plans to launch upto five nutraceutical products in India through partnerships with intt firms in 6 months

Elder Pharmaceuticals today said it has launched 'Zalain', a medicine used to treat fungal skin infections, in India in association with Spain-based drug firm Ferrer.

Elder Pharmaceuticals today said it has launched 'Zalain', a medicine used to treat fungal skin infections, in India in association with Spain-based drug firm Ferrer.

"Zalain has been introduced in India as part of company's strategy to strengthen its anti-infectives division which stood at about Rs 113.61 crore in FY 2012 and contributed 10% to the total revenue," Elder Pharmaceuticals Ltd Joint Managing Director Alok Saxena said in a statement.

The company is also planning to launch up to five in India through partnerships with international firms in next six months as it looks to strengthen position in the segment in the domestic market.

The Mumbai-based drug firm at present markets various nutraceutical products in the country, including calcium supplement 'Shelcal'. Its product portfolio consists licensed as well as own brands.

Elder Pharma's revenues for the financial year ended March 2012 stood at Rs 981.89 crore.

Shares of today closed at Rs 302.15 on the BSE, up 2.25% from its previous close.

image